Chr. Olesen Synthesis
2011
FOUNDED
PRIVATE
STATUS
Series A
LATEST DEAL TYPE
$11.3M
LATEST DEAL AMOUNT
1
INVESTORS
Description
Manufacturer of active pharmaceutical ingredients (APIs) and advanced intermediates designed to produce controlled substances comprising semi-synthetic opioids. The company is focused on controlled substances and molecules like Buprenorphine, Codeine Phosphate, Dexamfetamine, Hydromorphone and Lisdexamfetamine and also offers an election of other APIs like Pramipexole, Risedronate, Terbinafine and Tolfenamic Acid as well as advanced intermediates, enabling pharmaceutical clients to avail advanced intermediates and APIs.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
- Kanalholmen 8-12
- 2650 Hvidovre
- Denmark
+45 36 00 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Chr. Olesen Synthesis’s full profile, request a free trial.
Chr. Olesen Synthesis Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 01-Oct-2015 | $11.3M | 000.00 | Completed | Generating Revenue |
Chr. Olesen Synthesis Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 | 01-Jan-2011 | 000000000 | Distributors (Healthcare) |
Chr. Olesen Synthesis Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 | 01-Jan-2011 | 000000000 | Completed |
|
Chr. Olesen Synthesis Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Signet Healthcare Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 |
Chr. Olesen Synthesis Executive Team (4)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Thomas Moestrup | Chief Executive Officer & Managing Director | ||
| Erik Fischer | Head, API Development | ||
| Lone Nielsen | Finance & Administration Manager | ||
| Mads Olesen | Chairman |
Chr. Olesen Synthesis Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| James Gale | Signet Healthcare Partners | Board Member | 000 0000 | |
| Mads Olesen | Chr. Olesen Synthesis | Chairman | 000 0000 |